5 Best UK Stocks To Buy Now

3. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Investors In Q2 2023: 46

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biotechnology company that is developing treatments for diseases that are a result of immune system complications. Like AstraZeneca, its shares are also rated Strong Buy on average, and analysts have set an average share price target of $16.22.

By the end of 2023’s second quarter, 46 hedge funds among the 910 surveyed by Insider Monkey had bought and invested in Roivant Sciences Ltd. (NASDAQ:ROIV)’s shares. The firm’s largest shareholder in our database is Daniel Gold’s QVT Financial courtesy of its $1.2 billion investment.

Follow Roivant Sciences Ltd.